Welcome to our dedicated page for Bionano Genomics SEC filings (Ticker: BNGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bionano Genomics, Inc. (NASDAQ: BNGO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer, Bionano submits annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K that describe its financial condition, results of operations, risk factors and material corporate events.
Bionano’s recent Forms 8-K include disclosures about quarterly financial results, such as reports for the second and third quarters of 2025, and about capital markets transactions, including a September 2025 public offering of common stock and Series E and Series F warrants. The company has also filed a registration statement on Form S-1 relating to offerings of common stock, pre-funded warrants and warrants, which outlines offering terms, risk factors and use of proceeds.
Through this page, users can review Bionano’s descriptions of its business as a provider of optical genome mapping (OGM) solutions, diagnostic services and software, as well as its discussion of revenue sources, cost structure and liquidity. Filings may also include information on shareholder votes, such as the corrected voting results reported in an 8-K/A filed in June 2025, and details of securities purchase agreements and engagement letters with placement agents for public offerings.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify topics such as OGM adoption, consumables and software utilization, capital raises and going concern considerations. Investors can use this resource to track Bionano’s Forms 10-K and 10-Q for comprehensive financial statements, Forms 8-K for event-driven updates, and registration statements for securities offerings, while AI-generated insights assist in understanding the implications of each filing.
Bionano Genomics (BNGO) received a Schedule 13G disclosing that Lind Global Fund III LP and related reporting persons beneficially own 1,005,961 shares of common stock, representing 9.9% of the class. The disclosed position comprises 525,000 shares, 525,000 Series E warrants and 525,000 Series F warrants, and the filing explicitly states the warrants may not be exercised to cause ownership to exceed 9.9%. The filing identifies Lind Global Partners III LLC as the general partner and Jeff Easton as managing member, with sole voting and dispositive power over the reported holdings. The reporting persons certify the holdings were not acquired to change or influence control.
Bionano Genomics, Inc. reporting persons CVI Investments, Inc. and Heights Capital Management, Inc. disclose collective beneficial ownership of 1,021,671 shares of common stock, representing 9.9% of the class. The reported holdings consist of 475,000 shares plus additional shares issuable upon exercise of warrants, with exercise limited so ownership does not exceed 9.99%.
Heights Capital Management serves as investment manager to CVI Investments and may be deemed to share voting and dispositive power over the reported shares; both entities disclaim beneficial ownership except for pecuniary interest. Exhibits include a Limited Power of Attorney and a Joint Filing Agreement.
Reporting persons Intracoastal Capital LLC, Mitchell P. Kopin and Daniel B. Asher disclose shared beneficial ownership in Bionano Genomics common stock equal to 4.99% of the outstanding class. The filing explains that the ownership position arises from warrants and shares issued or issuable under a Securities Purchase Agreement and that certain warrants include blocker provisions preventing exercise to the extent such exercise would push beneficial ownership above 4.99%. The reporting persons state shared voting and dispositive power over 508,415 shares issuable upon exercise of a warrant and note that, without blocker provisions, their aggregate beneficial interest could be materially larger.
Iroquois Capital Management, LLC and two related individuals disclosed ownership stakes in Bionano Genomics common stock. Iroquois reports beneficial ownership of 367,500 shares (3.8%). Richard Abbe reports aggregate ownership of 525,000 shares (5.4%), and Kimberly Page reports 367,500 shares (3.8%). The filing states that certain warrants exercisable into additional shares (totaling 1,050,000 shares across reporting persons) exist but are subject to 4.99% beneficial ownership blockers that currently prevent their exercise. The cover pages show shared voting and dispositive power for portions of the holdings and clarify that percentages reflect the 9,755,265 shares outstanding referenced in the company prospectus.
Bionano Genomics, Inc. filed a Form 8-K reporting a material corporate event and attached transaction documents. The filing lists exhibit materials that include the Form of Pre-Funded Warrant, Form of Series E/F Warrant, and a Form of Securities Purchase Agreement. It also includes two press releases: one dated September 16, 2025 announcing the pricing of an Offering, and one dated September 17, 2025 announcing the closing of the Offering. The filing provides the company’s registered details and Nasdaq listing (BNGO) but does not disclose transaction amounts, share counts, or other financial terms within the text provided.
Lincoln Alternative Strategies LLC reported beneficial ownership of 525,000 shares of Bionano Genomics, Inc. common stock, representing 5.42% of the 9,680,265 shares outstanding as of September 17, 2025. The filing indicates Lincoln has sole voting and dispositive power over these shares and states the holdings were not acquired to change or influence control of the issuer. The statement is submitted on a Schedule 13G under the Securities Exchange Act.
Bionano Genomics, Inc. (BNGO) is offering 4,925,000 shares of common stock, 75,000 pre-funded warrants and 10,000,000 warrants (Series E and F) that together could result in 10,075,000 shares if exercised. The prospectus discloses expected closing and delivery around September 17, 2025 and a Nasdaq closing stock price of $2.77 per share on September 15, 2025. Estimated net proceeds after placement agent fees and offering expenses are approximately $9.0 million. Placement agent compensation totals 6.0% cash fee plus 0.5% management fee and specified expense reimbursements. The company warns of a limited trading market and liquidity for the Pre-Funded Warrants and Warrants, and states it needs significant additional financing and must manage costs to continue as a going concern within 12 months of its Form 10-Q for the quarter ended June 30, 2025. The prospectus lists outstanding potential dilution: 191,532 option shares, 2,081,089 warrant shares, 633,704 convertible-note shares and various plan reserves.
Amended Form 4: Mark Oldakowski, Chief Operating Officer of Bionano Genomics, reported an amended insider transaction related to restricted stock units. On 09/11/2025 a grant of RSUs vested and the issuer withheld 59 shares to satisfy tax withholding obligations at a reported price of $4.06 per share. After the withholding, the reporting person beneficially owned 915 shares of Bionano Genomics common stock on a direct basis. The amendment was filed on 09/12/2025 and is limited to reporting the share withholding related to the RSU settlement that originally vested on 09/11/2025.
Bionano Genomics, Inc. (BNGO) filed a registration statement on Form S-1 to offer securities, with delivery expected in 2025. The prospectus discloses a planned offering with estimated net proceeds of approximately $9.0 million after placement agent fees and estimated offering expenses. Placement agent compensation includes a 6.0% cash fee, a 0.5% management fee, and reimbursement caps for legal and other costs. The company warns of material risks, including the need for significant additional financing to continue as a going concern within 12 months of its June 30, 2025 quarter filing. Corporate provisions described include Delaware Section 203 anti-takeover protections, a Court of Chancery exclusive forum provision, indemnification for directors and officers, and outstanding dilutive instruments: 191,532 options, 2,081,088.57 warrants, and 633,703.70 shares issuable on convertible notes. Recent private placements in 2023 and 2024 are summarized and certain exhibits contain redactions.
Bionano Genomics, Inc. reported interim unaudited results showing recurring losses and cash constraints. As of June 30, 2025 the company held $3.6 million in cash and cash equivalents, $12.9 million in short-term investments, $11.0 million in restricted short-term investments and working capital of $18.5 million. The company had $12.1 million principal outstanding under its senior secured convertible debentures and an accumulated deficit of $703.2 million. The company used $6.3 million of cash in operations during the six months ended June 30, 2025 and management stated there is substantial doubt about its ability to continue as a going concern without raising additional capital. Management expects operating losses and negative cash flows to continue for at least the next year and believes existing resources are sufficient into at least the first quarter of 2026 assuming current plans. Significant financing and conversion activity included a reverse stock split (1-for-60), registered direct offerings in January 2025 (~$10.0 million gross proceeds) and at-the-market sales under an ATM Agreement with H.C. Wainwright in 2025 (multiple tranches totaling millions in gross proceeds). Restructuring actions in 2023 and 2024 reduced headcount and caused related charges and impairments previously recorded.